Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTXNASDAQ:HLVXNASDAQ:KYTXNASDAQ:LIAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.59-1.2%$1.68$1.20▼$7.66$90.12M2.811.49 million shs417,401 shsHLVXHilleVax$1.85$1.69$1.34▼$16.31$92.76M0.86441,850 shs190,157 shsKYTXKyverna Therapeutics$2.10-1.9%$2.31$1.78▼$17.55$90.76M2.57425,049 shs153,952 shsLIANLianBio$0.19+8.6%$0.20$0.27▼$4.99$20.54M0.231.04 million shs11,404 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%+10.42%-4.79%-35.89%-68.58%HLVXHilleVax0.00%+9.47%+14.91%-6.09%-85.29%KYTXKyverna Therapeutics0.00%+12.90%-11.02%-41.67%-88.14%LIANLianBio+8.63%-4.95%+0.11%+2.70%-32.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDTXBlack Diamond Therapeutics3.4647 of 5 stars3.54.00.00.03.12.51.3HLVXHilleVax2.8109 of 5 stars3.02.00.00.03.13.31.3KYTXKyverna Therapeutics2.0663 of 5 stars3.53.00.00.03.80.00.0LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.00Buy$14.60818.24% UpsideHLVXHilleVax 2.00Hold$3.0062.16% UpsideKYTXKyverna Therapeutics 3.00Buy$18.33773.02% UpsideLIANLianBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LIAN, HLVX, BDTX, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/31/2025HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/19/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/18/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.003/7/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/7/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00 ➝ $11.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$2.26 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/AKYTXKyverna Therapeutics$7.03M12.91N/AN/AN/A∞LIANLianBioN/AN/AN/AN/A$2.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$82.44M-$1.27N/AN/AN/AN/A-68.08%-49.65%5/8/2025 (Estimated)HLVXHilleVax-$123.57M-$3.00N/AN/AN/AN/A-67.27%-51.99%5/8/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.47N/AN/AN/AN/A-51.12%-37.91%5/13/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ALatest LIAN, HLVX, BDTX, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21N/AN/AN/AN/AN/A5/8/2025Q1 2025BDTXBlack Diamond Therapeutics$0.10N/AN/AN/A$23.33 millionN/A5/8/2025Q1 2025HLVXHilleVax-$0.37N/AN/AN/AN/AN/A3/28/2025Q4 2024HLVXHilleVax-$0.33-$0.35-$0.02-$0.68N/AN/A3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/6/2025Q4 2024BDTXBlack Diamond Therapeutics-$0.31-$0.28+$0.03-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A5.555.55HLVXHilleVaxN/A14.2514.25KYTXKyverna TherapeuticsN/A10.5010.50LIANLianBioN/A10.0610.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%HLVXHilleVax86.42%KYTXKyverna Therapeutics18.08%LIANLianBio74.85%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics8.87%HLVXHilleVax71.10%KYTXKyverna TherapeuticsN/ALIANLianBio7.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.68 million51.57 millionOptionableHLVXHilleVax2050.14 million14.39 millionNot OptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableLIANLianBio110108.06 million99.86 millionNot OptionableLIAN, HLVX, BDTX, and KYTX HeadlinesRecent News About These CompaniesWith Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisitionOctober 9, 2024 | fiercebiotech.comChina's Zeekr prices US IPO at top of range to raise $441 millionMay 10, 2024 | msn.comExclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source saysMay 9, 2024 | msn.comWhy Is LianBio (LIAN) Stock Moving Today?March 15, 2024 | investorplace.comLianBio Announces Voluntarily Delisting from NasdaqFebruary 28, 2024 | globenewswire.comWith No Cure In Sight, Drugs Firm LianBio Begins Exit StrategyFebruary 23, 2024 | seekingalpha.comLianBio to shut down, return cash to investorsFebruary 14, 2024 | biopharmadive.comLianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-MarketFebruary 13, 2024 | markets.businessinsider.comLianBio to Wind Down Operations, Declares Special DividendFebruary 13, 2024 | marketwatch.comLianBio Shares Gain After Co Announces Plans to Wind DownFebruary 13, 2024 | marketwatch.comLianBio Announces Completion of Strategic ReviewFebruary 13, 2024 | finance.yahoo.comB of A Securities Downgrades LianBio: Here's What You Need To KnowJanuary 3, 2024 | markets.businessinsider.comNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | markets.businessinsider.comLianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | finance.yahoo.comInterest Is Growing for Smaller, More Speculative NamesDecember 20, 2023 | realmoney.thestreet.comLianBio Announces Departure of Chief Financial OfficerDecember 20, 2023 | finance.yahoo.comLianBio Names Stone as Interim CEO as Wang ResignsDecember 19, 2023 | marketwatch.comLianBio Announces Departure of Chief Executive OfficerDecember 19, 2023 | finance.yahoo.comLianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesDecember 6, 2023 | finance.yahoo.comLianBio Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesDecember 1, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonIntel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround HopesVenezuelan Tariffs Could Power These 3 Diesel-Driven WinnersBy Gabriel Osorio-Mazilli | March 30, 2025View Venezuelan Tariffs Could Power These 3 Diesel-Driven WinnersMeta Eyes India: Breaking Down Its Quest for Reliance PartnershipBy Leo Miller | April 7, 2025View Meta Eyes India: Breaking Down Its Quest for Reliance PartnershipLIAN, HLVX, BDTX, and KYTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.59 -0.02 (-1.24%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.57%) As of 04/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.HilleVax NASDAQ:HLVX$1.85 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.85 0.00 (0.00%) As of 04/25/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$2.10 -0.04 (-1.87%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.10 0.00 (0.00%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.LianBio NASDAQ:LIAN$0.19 +0.02 (+8.63%) As of 04/25/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
